R

Roche

Global pharmaceuticals and diagnostics company

IT Infrastructure Engineer

Full-TimeUpdated on 10/23/2026
No salary listed
Mid, Senior
Master's
Madrid, Spain
HybridHybrid position, split evenly between infrastructure engineering and automation/coding; no office/home attendance schedule is specified.
DevOps & InfrastructurePlatform Engineering, DevOps Engineering

About the job

Requirements
  • Three to six years of relevant work experience, or one to three years with a Master's degree; experience in a multinational work environment is preferred.
  • Demonstrated experience acting in a DevOps capacity and independently addressing a broad range of difficult technical problems.
  • Experience designing, building, testing, and implementing integrated, reliable IT infrastructure solutions.
  • Experience representing workgroups on project teams and managing milestones; experience leading small project teams or mentoring individuals may be needed.
  • Proven experience designing and managing backup environments, specifically using Cohesity.
  • Strong proficiency in Python for automation, with foundational coding skills adaptable to other programming languages.
  • Hands-on experience with Ansible, Jenkins, or equivalents, and strong proficiency in RESTful API design principles and integration workflows.
  • Strong proficiency in Git and GitHub for distributed version control, collaborative workflows, and code management.
  • Strong understanding of best practices and IT operations in an always-up, always-available service environment, applying Scrum, Agile, and ITIL methodologies.
  • Ability to evaluate promising technologies via proofs of concept and assess their feasibility in meeting business needs.
Responsibilities
  • Design, build, test, and implement integrated, resilient, and reliable infrastructure backup solutions on premises or in the public cloud.
  • Apply technical knowledge independently to address difficult challenges and solve a wide range of business problems.
  • Monitor operational challenges and work with product and support teams to provide internal escalation support and resolve incidents and major incidents.
  • Ensure implemented solutions comply with Quality and Regulatory standards.
  • Design and implement test-driven infrastructure and continuous deployment pipelines.
  • Provision, deliver, and manage infrastructure as code and orchestration systems to eliminate manual toil.
  • Produce and maintain documentation for designs, design patterns, and automated component standards created or maintained.
  • Evaluate promising technologies and assess business feasibility across technology domains through proofs of concept.
  • Act as a technical consultant to senior internal and external stakeholders, clearly communicating complex issues and solutions.
  • Own key project deliverables, represent the workgroup, and influence project direction and technical decisions.
  • Collaborate with diverse team members and virtual teams across locations and cultural backgrounds.
Desired Qualifications
  • Knowledge of disaster recovery, cyber recovery, and backup tools such as Rubrik, Veeam, or Commvault.
  • Experience with hypervisor technologies, specifically Nutanix AHV (Acropolis Hypervisor) and VMware ESXi.
  • Familiarity with PowerShell for existing scripts and vendor modules, such as Cohesity.
  • Linux administration and operating-system troubleshooting background to support infrastructure-as-code development, including Bash or shell scripting.
  • Solid understanding of the IT Service Management lifecycle; ITIL 4 Foundation certification is highly desired.
  • Early experience or strong interest in building AI agent workflows and using Model Context Protocol to integrate AI capabilities into core system integrations.

About the company

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Get referred to Roche

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Enicepatide delivered 15.5% weight loss in September 2026 and 22.7% in June.
  • pTau217 can scale immediately through Roche's existing lab network and improve Alzheimer diagnostics.
  • Roche's June 2026 data and September 2026 filings signal multiple obesity shots on goal.

What critics are saying

  • Eli Lilly and Novo Nordisk dominate obesity pricing, distribution, and physician mindshare today.
  • Enicepatide remains Phase II-only; Roche starts late-stage glycemic and cardiovascular studies in 2027.
  • If enicepatide disappoints, Roche burns its $2.7 billion Carmot bet and loses obesity credibility.

What makes Roche unique

  • Roche combines pharma, diagnostics, and installed cobas labs across 4,500 U.S. instruments.
  • Elecsys pTau217 won FDA clearance on August 24, 2026, and CE marking September 7.
  • Roche controls obesity assets from Carmot and Zealand, spanning GLP-1/GIP and amylin.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Performance Bonus

Company News

Yahoo Finance
Oct 22nd, 2026
Roche reaffirms outlook as Q3 sales rise 7% to $19.6B, but growth doubts linger

Roche reaffirmed its 2025 outlook on Thursday and beat third-quarter sales expectations, but questions about its long-term growth remain. Group sales rose 7% to 16.1 billion Swiss francs (about $19.6 billion), ahead of the 15.8 billion franc consensus estimate. Jefferies analyst Michael Leuchten said a new resource planning system boosted revenue, making the results "cosmetically ahead." Roche still expects group sales growth in the "mid single digit range" and did not raise guidance. Sales of allergy and asthma drug Xolair reached only 848 million francs, well below estimates. A copycat version launched in the US this month, and Ocrevus and Tecentriq face generic competition by 2030. Roche is counting on its breast cancer pill giredestrant, which awaits a US Food and Drug Administration decision by December 18, and on obesity drugs. It says the products could together reach $9 billion in peak annual sales.

CNBC
Oct 22nd, 2026
Roche CEO presses Germany on growth strategy as drugmaker pauses investment there

Roche chief executive officer Thomas Schinecker has challenged Germany over its growth strategy, saying pharmaceutical firms are "the industry they need to bet on." Schinecker discussed the company's third-quarter earnings and its recent expansion in China. He also outlined recent pharmaceutical developments at the business. He explained why Roche has paused investment in Germany.

Yahoo Finance
Oct 16th, 2026
FDA approves Roche's Enspryng as first at-home injection for thyroid eye disease

Roche said the US Food and Drug Administration (FDA) has approved Enspryng (satralizumab) for adults with thyroid eye disease (TED). It is the first and only at-home subcutaneous treatment for the condition, and a patient or caregiver can administer it after training. In the Phase III SatraGO-2 trial, 52.9% of active TED patients on Enspryng had a proptosis (eye bulging) response, against 23.4% on placebo. Double vision fell in 60.7% of patients, against 25.8%. The SatraGO-1 trial missed its primary endpoint at Week 24. No new safety signals emerged. TED affects about 155 in every 100,000 people in the US. This is Enspryng's second approval, after neuromyelitis optica spectrum disorder in 2020. The FDA is also reviewing it for myelin oligodendrocyte glycoprotein antibody-associated disease, with a decision expected in January 2027.

Yahoo Finance
Oct 9th, 2026
FDA approves Roche's Tecentriq for stage III colon cancer, cutting recurrence risk by 50%

The US Food and Drug Administration has approved Roche's Tecentriq in combination with a fluoropyrimidine and oxaliplatin for adjuvant treatment of stage III deficient DNA mismatch repair colon cancer. This marks Tecentriq's twelfth approved indication in the US. The approval follows the phase III ATOMIC study, published in The New England Journal of Medicine, which demonstrated that Tecentriq plus chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone. The 36-month disease-free survival rate was 86% with the combination versus 76% with chemotherapy alone. Nearly 25% of colon cancers are diagnosed at stage III, and almost one in three stage III patients experience recurrence within five years. This represents the first approved adjuvant immunotherapy regimen for this patient population. Roche is pursuing further regulatory filings, including with the European Medicines Agency.

Yahoo Finance
Sep 30th, 2026
Roche's enicepatide shows 22.5% weight loss in 48 weeks, challenging Eli Lilly and Novo Nordisk

Roche posted strong Phase 2 results for its weight loss drug enicepatide, showing 22.5% mean weight loss over 48 weeks. This compares favourably to Eli Lilly's Zepbound, which achieved 20.2% weight loss over 72 weeks in a separate trial. In another Phase 2 study, enicepatide demonstrated HbA1c reductions of up to 2.65 percentage points in diabetic patients after 48 weeks, compared to tirzepatide's 2.37 percentage points after 52 weeks. Despite promising results, Roche faces stiff competition from Novo Nordisk and Eli Lilly, which both have deep pipelines in development. Novo Nordisk's CagriSema is nearing approval, whilst Eli Lilly's retatrutide has posted strong Phase 3 results. Roche's revenue grew 6% year over year in the first half of the year to 30.4 billion Swiss francs.